Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Plasma metabolomics, a branch of metabolomics focused on analyzing small molecules (metabolites) in blood plasma, plays a promising role in the prevention of metabolic dysfunction-associated steatohepatitis (MASH) and...
Exosome-related genes have gained significant attention for their potential role in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) to hepatocellular carcinoma (HCC)....
The study you provided investigates the relationship between normal ALT (alanine transaminase) levels, liver fibrosis, and metabolic dysfunction-associated steatotic liver disease (MASLD). Here's a detailed breakdown of the...
Yes, rapamycin alleviates intrahepatic inflammation in metabolic dysfunction-associated steatotic liver disease (MASLD). According to the study, rapamycin's therapeutic effects are primarily mediated through its action on bone marrow-derived...
Fisetin, a natural flavonoid found in fruits and vegetables like strawberries and apples, has shown significant potential in combating metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD, a chronic...
Survodutide is emerging as a promising treatment for metabolic dysfunction–associated steatohepatitis (MASH), a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD). Survodutide functions as a dual agonist...
Efruxifermin (EFX) is a promising treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe progression of metabolic liver disease with limited effective therapies. EFX is a fibroblast growth factor...
The global burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is rising at an alarming rate and poses a significant public health challenge. MASLD...
The spleen-to-liver stiffness ratio (SSM/LSM) is an emerging noninvasive biomarker that has shown significant potential in characterizing portal hypertension (PH), particularly in patients with metabolic dysfunction-associated steatohepatitis (MASH)....
GLP-1 receptor agonists (such as semaglutide and liraglutide) and the dual GLP-1/GIP receptor agonist tirzepatide have been studied for their impact on major adverse liver outcomes (MALO) in...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.